Dulaglutide vs Liraglutide

How they're alike

Dulaglutide and liraglutide are both injectable GLP-1 receptor agonists developed to overcome the ~2-minute plasma half-life of native GLP-1, which is cleaved at the His7–Ala8 scissile bond by dipeptidyl peptidase-4. Both engineer around that limitation by combining (i) a modification at position 2 of the GLP-1 backbone that blocks DPP-4 cleavage and (ii) a half-life-extending tag that prevents rapid renal clearance — a γ-Glu-C16 fatty-acid spacer at Lys26 for liraglutide, and a peptide-linker-tethered IgG4-Fc dimer for dulaglutide (Knudsen 2019; Jendle 2016). At the GLP-1 receptor itself both drugs drive the same downstream pharmacology: glucose-dependent insulin secretion from pancreatic β-cells, suppression of α-cell glucagon release, delayed gastric emptying, and central nervous system satiety signaling. Both have established efficacy for HbA1c reduction in type 2 diabetes and both have demonstrated reduction of major adverse cardiovascular events (3P-MACE) in dedicated cardiovascular outcomes trials in T2D populations — liraglutide in LEADER and dulaglutide in REWIND (Gerstein 2019).

How they differ

The most important difference is molecular architecture, and almost every other difference flows from it. Liraglutide is a 30-residue GLP-1 analog acylated with a C16 palmitic-acid chain via a γ-glutamic-acid spacer on Lys26; the fatty acid drives reversible non-covalent albumin binding and yields a half-life of roughly 13 hours, consistent with once-daily subcutaneous dosing (Knudsen 2019). Dulaglutide is a much larger molecule — two GLP-1(7-37) analog chains, each carrying an Aib substitution at position 2, covalently linked through short peptide connectors to an IgG4-Fc fragment, giving an ~59.7 kDa homodimer whose half-life of approximately 4.5 days is driven by FcRn-mediated endosomal recycling and supports once-weekly subcutaneous administration (Jendle 2016). The two sequences are close at the GLP-1 backbone level — 93.3% identity over 30 aa, differing essentially at position 2 (where dulaglutide uses Aib for DPP-4 resistance and liraglutide retains alanine, deriving its protease resistance instead from albumin shielding) and near the C-terminus — but the relevant biology lives in what is attached to that backbone rather than in the backbone alone.

Indication footprints have diverged accordingly. Liraglutide is approved for type 2 diabetes (Victoza, 2010) and, separately, for chronic weight management (Saxenda, 2014), including in adolescents 12–17, and was the first GLP-1 receptor agonist to demonstrate cardiovascular mortality benefit in a dedicated outcomes trial (Knudsen 2019). Dulaglutide is approved for glycemic control in type 2 diabetes (Trulicity, September 2014) with a cardiovascular risk reduction indication added in 2020 on the basis of REWIND, but has no obesity indication: at its approved 0.75 mg and 1.5 mg doses it produces only modest weight loss in T2D populations (Jendle 2016; Gerstein 2019). The AWARD program established that dulaglutide 1.5 mg once weekly delivers HbA1c reductions of approximately 1.3–1.6 percentage points from baseline across diverse backgrounds — superior to sitagliptin, exenatide BID, and metformin monotherapy in the relevant AWARD trials (Jendle 2016).

Head-to-head clinical evidence

The direct head-to-head comparison is AWARD-6, an open-label phase 3 non-inferiority trial in metformin-treated adults with type 2 diabetes comparing once-weekly dulaglutide 1.5 mg with once-daily liraglutide 1.8 mg over 26 weeks (Jendle 2016). The primary HbA1c reduction was –1.42% with dulaglutide versus –1.36% with liraglutide, meeting the prespecified non-inferiority margin of 0.25%. AWARD-6 is the trial that established weekly dulaglutide as glycemically equivalent to the maximum approved diabetes dose of daily liraglutide — a key step in the broader shift from daily to weekly GLP-1 dosing in T2D practice.

A separate phase 3 head-to-head in Japanese patients with type 2 diabetes compared once-weekly dulaglutide with once-daily liraglutide over 52 weeks and reported a significantly larger HbA1c reduction with dulaglutide in that population (Inagaki 2016). Beyond these randomized head-to-head trials, the comparative literature has been extended by real-world cohort studies and observational meta-analyses, including comparative work in Asian T2D cohorts and comparative cardiovascular/renal outcome analyses, which broadly find the two drugs deliver similar glycemic effect with route-, schedule-, and adherence-driven practical differences rather than a clean efficacy gap. Both compounds also appear as comparator arms in network meta-analyses anchored on semaglutide and tirzepatide.

Safety profile comparison

The two drugs share the GLP-1 class safety profile. Gastrointestinal adverse events — nausea, vomiting, diarrhea — are the most common and dose-limiting; for both agents these are most pronounced during the initial titration weeks and attenuate with continued treatment. In REWIND, nausea occurred in 10.3% of dulaglutide-treated patients versus 5.0% on placebo, and diarrhea in 12.8% versus 10.4%; pancreatitis events were balanced between arms and no excess thyroid malignancy was seen (Gerstein 2019). The AWARD program reported a similar GI-predominant profile for dulaglutide, with low background hypoglycemia rates except when combined with insulin or sulfonylureas (Jendle 2016). Liraglutide's published safety experience covers nausea, vomiting, diarrhea and constipation across SCALE, LEAD and LEADER, with the boxed thyroid C-cell tumor warning, pancreatitis caution, and gallbladder-related adverse events shared as a class signal across both molecules (Knudsen 2019). Both carry the class boxed warning against use in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Injection-site reactions occur more often with daily liraglutide than with weekly dulaglutide, simply as a function of injection frequency.

A practical safety/tolerability dimension that does separate the two is dosing schedule: weekly dulaglutide delivered through a prefilled, hidden-needle autoinjector reduces injection burden compared with daily liraglutide. Population-level adherence and persistence studies referenced in the comparative literature consistently favor once-weekly over once-daily injectable GLP-1 receptor agonists in T2D care.

Indication overview

Liraglutide is FDA-approved for adults and pediatric patients aged 10 and older with type 2 diabetes (Victoza, 2010) and for chronic weight management in adults and adolescents aged 12–17 (Saxenda, 2014); it was the first GLP-1 receptor agonist with an obesity indication and the first with a demonstrated reduction in major adverse cardiovascular events in a dedicated outcomes trial (Knudsen 2019). Dulaglutide is FDA-approved for glycemic control in adults with type 2 diabetes (Trulicity, September 2014); a cardiovascular risk reduction indication was added in 2020 on the basis of REWIND, which extended the cardiovascular benefit signal to a T2D population that included patients without established cardiovascular disease at baseline (Gerstein 2019). Dulaglutide does not have an approved indication for chronic weight management. Where weekly versus daily injection cadence, the presence or absence of an obesity indication, the availability of a pediatric/adolescent label, and the breadth of the cardiovascular outcomes evidence are clinically relevant considerations, the contrast between the two molecules sits primarily along those structured-indication axes rather than along a single efficacy gradient.